Sorafenib
- PDF / 169,490 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 51 Downloads / 148 Views
1 S
Various toxicities: case report A 69-year-old woman developed diarrhoea, anaemia, fatigue, renal dysfunction and hand-foot syndrome (HFS) while receiving treatment with sorafenib [route not stated] for advanced hepatocellular carcinoma (HCC). The woman, who had chronic hepatitis C received transcatheter arterial chemoembolisation for multiple HCC tumors. After 13 months of transcatheter arterial chemoembolisation, CT scan revealed multiple liver and lung tumors with significant elevation of the serum tumor markers alpha foetoprotein (AFP) and protein induced by vitamin K absence/antagonist-II (PIVKA-II). Subsequently, she was started on sorafenib 400mg daily. After 2 months of initiation of treatment, she presented with anaemia, diarrhoea, renal dysfunction, fatigue and HFS as adverse events of sorafenib. The woman’s treatment with sorafenib was discontinued, and she was hospitalised for severe anaemia with haemoglobin level of 3.7 g/dL. Following blood transfusion, her anaemia improved. After discontinuation of sorafenib, other adverse related to sorafenib also improved. Hirose S, et al. A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy. Clinical 803516304 Journal of Gastroenterology 13: 902-906, No. 5, Jun 2020. Available from: URL: http://doi.org/10.1007/s12328-020-01154-z
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
